Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cromoglicate→

Cromoglicate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
16110-51-3
Molecular formula
C23H16O11
Molecular weight
468.4 g/mol
Drug class
Mast-cell stabiliseranti-allergic agent (cromoglicic acid)
Mechanism of action
Inhibits activation and mediator release from sensitised mast cells and other inflammatory cells. The precise molecular mechanism is not fully established; it acts prophylactically and is not a rapid bronchodilator. Sodium cromoglicate is a salt of the same active moiety.
Indications / reported uses
  • Prevention of bronchial asthma symptoms with inhaled formulations
  • Treatment or prevention of allergic rhinitis with nasal formulations
  • Relief of allergic conjunctivitis with ophthalmic formulations
  • Selected systemic use for mastocytosis with oral formulations; use is route- and product-specific

Sources: US DailyMed — Cromolyn sodium products · NHS — Sodium cromoglicate · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Mast-cell stabiliser; anti-allergic agent (cromoglicic acid)

Mechanism of action

Inhibits activation and mediator release from sensitised mast cells and other inflammatory cells. The precise molecular mechanism is not fully established; it acts prophylactically and is not a rapid bronchodilator. Sodium cromoglicate is a salt of the same active moiety.

General use cases

  • Prevention of bronchial asthma symptoms with inhaled formulations
  • Treatment or prevention of allergic rhinitis with nasal formulations
  • Relief of allergic conjunctivitis with ophthalmic formulations
  • Selected systemic use for mastocytosis with oral formulations; use is route- and product-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cromoglicate Environmental Risk Assessment (ERA) (the Cromoglicate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.